Eur J Cancer: Real clinical practice data of anti-PD-1 adjuvant treatment of melanoma!

Melanoma, usually referred to as malignant melanoma, is a highly malignant tumor derived from melanocytes, referred to as malignant melanoma, which occurs mostly in the skin, but also in mucous membranes and internal organs, accounting for about 3% of all tumors
.
Skin malignant melanoma accounts for the third place (about 6.

8%~20%) of skin malignant tumors

child

Although there are many clinical trials on the adjuvant therapy of melanoma, there are few data on the prognosis of melanoma patients who receive adjuvant therapy in the clinic
.
Starting in 2019, adjuvant melanoma patients will be registered on the DMTR ( a population-based registry for monitoring the quality and safety of melanoma diagnosis and treatment in the Netherlands )

.

Diagnosis and treatment

This study aims to analyze the treatment mode, recurrence rate and adverse event rate of melanoma patients who actually receive adjuvant therapy in clinical practice through the patient data registered on the DMTR
.

Patients with melanoma who had received adjuvant therapy on DMTR were included
.
Use descriptive statistics to analyze patient characteristics and treatment characteristics

.

PFS of melanoma patients of different stages receiving adjuvant anti-PD-1 therapy

PFS of melanoma patients of different stages receiving adjuvant anti-PD-1 therapy

A total of 641 melanoma patients receiving adjuvant anti-PD-1 therapy were enrolled
.
After a median follow-up of 12.

8 months, the 12-month relapse-free productivity was 70.

After a median follow-up of 12.

Grade 3 and above toxic reactions during or after anti-PD-1 treatment

Grade 3 and above toxic reactions during or after anti-PD-1 treatment

In summary, compared with clinical practice, in daily practice, anti-PD-1 adjuvant therapy after resection of stage III/IV melanoma showed a slightly higher toxicity rate and higher frequency of early discontinuation, but no progress Survival rates are similar

.

Compared with clinical practice, in daily practice, anti-PD-1 adjuvant therapy after resection of stage III/IV melanoma shows a slightly higher toxicity rate and higher frequency of early discontinuation, but the progression-free survival rate is similar to clinical practice Compared with practice, in daily practice, anti-PD-1 adjuvant therapy after resection of stage III/IV melanoma shows a slightly higher toxicity rate and higher frequency of early discontinuation, but the progression-free survival rate is similar

Original source:

Original source:

de Meza Melissa M, Ismail Rawa K, Rauwerdink Daan et al.

Adjuvant treatment for melanoma in clinical practice - Trial versus reality in this message